That situation was due to product issues by two competitors. Ferring Pharmaceutical in September 2015 recalled 42 lots, more than 32,300 vials, of its fertility drug Bravelle because of potency concerns. Then in May, the other Merck ($MRK), known as MSD outside the U.S., reported a supply interruption for its ovulation-stimulating hormone Follistim. It said at the time that it expected the supply issue to be resolved this summer.